Ritter Pharmaceuticals is a company that creates novel therapeutic products to treat gastrointestinal diseases by modulating the gut microbiome. Their lead product, RP-G28, is currently in development and has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a condition that affects over 1 billion people worldwide. RP-G28 has successfully completed Phase 2 clinical trials, and Ritter Pharmaceuticals plans to partner with other companies for further development and commercialization of the drug.